» Articles » PMID: 33993814

Three-dimensional Bioprinting of Artificial Ovaries by an Extrusion-based Method Using Gelatin-methacryloyl Bioink

Overview
Journal Climacteric
Publisher Informa Healthcare
Date 2021 May 17
PMID 33993814
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The aim of this study was to design and fabricate a three-dimensional (3D) printed artificial ovary.

Methods: We first compared the printability of gelatin-methacryloyl (GelMA), alginate and GelMA-alginate bioinks, of which GelMA was selected for further investigation. The swelling properties, degradation kinetics and shape fidelity of GelMA scaffolds were characterized by equilibrium swelling/lyophilization, collagenase processing and micro-computed tomography evaluation. Commercial ovarian tumor cell lines (COV434, KGN, ID8) and primary culture ovarian somatic cells were utilized to perform cell-laden 3D printing, and the results were evaluated by live/dead assays and TUNEL detection. Murine ovarian follicles were seeded in the ovarian scaffold and their diameters were recorded every day. Finally, maturation was performed, and the ovulated oocytes were collected and observed.

Results: Our results indicated that GelMA was suitable for 3D printing fabrication. Its scaffolds performed well in terms of hygroscopicity, degradation kinetics and shape fidelity. The viability of ovarian somatic cells was lower than that of commercial cell lines, suggesting that extrusion-based 3D culture fabrication is not suitable for primary ovarian cells. Nevertheless, the GelMA-based 3D printing system provided an appropriate microenvironment for ovarian follicles, which successfully grew and ovulated in the scaffolds. Metaphase II oocytes were also observed after maturation.

Conclusions: The GelMA-based 3D printing culture system is a viable alternative option for follicular growth, development and transfer. Accordingly, it shows promise for clinical application in the treatment of female endocrine and reproductive conditions.

Citing Articles

3D bioprinting technology innovation in female reproductive system.

Chen S, Wang T, Chen J, Sui M, Wang L, Zhao X Mater Today Bio. 2025; 31:101551.

PMID: 40026632 PMC: 11870202. DOI: 10.1016/j.mtbio.2025.101551.


Research advances in the construction of stem cell-derived ovarian organoids.

Zhang T, Zhang M, Zhang S, Wang S Stem Cell Res Ther. 2024; 15(1):505.

PMID: 39736770 PMC: 11687137. DOI: 10.1186/s13287-024-04122-3.


Development and Applications of Organoids in Gynecological Diseases.

Yang J, Li W, Zhang Z, Xu Z, Zhu W, Wang J Stem Cell Rev Rep. 2024; .

PMID: 39666266 DOI: 10.1007/s12015-024-10833-0.


Application of Additive Manufacturing in Assisted Reproductive Techniques: What Is the Evidence? A Clinical and Technical Systematic Review of the Literature.

Kontogeorgi A, Boutas I, Tsangkalova G, Messaropoulos P, Koufopoulos N, Schwab R Medicina (Kaunas). 2024; 60(11).

PMID: 39597074 PMC: 11596948. DOI: 10.3390/medicina60111889.


Engineering mesenchymal stem cells for premature ovarian failure: overcoming challenges and innovating therapeutic strategies.

Yuan Z, Zhang Y, He X, Wang X, Wang X, Ren S Theranostics. 2024; 14(17):6487-6515.

PMID: 39479455 PMC: 11519806. DOI: 10.7150/thno.102641.